Menu
Menu
Menu
Neuromuscular disorders often slowly progress and affect each individual differently, making it difficult to assess drug efficacy quickly and accurately. With AMRA’s MRI scan you can assess 36+ different muscles with precision and detect small changes over time to better evaluate the impact of a drug candidate.
Advance your clinical trials for musculoskeletal and neuromuscular disorders with AMRA’s rapid, whole-body MRI protocol, precise muscle biomarkers, and regulatory strategy support.
We deliver key insights few others can offer—helping our partners make optimal decisions for research and development. Whether you are conducting a complex mechanistic study or a large-scale, international, multi-center imaging trial, we can get you precise muscle and muscle fat replacement measurements for numerous muscles throughout the entire body—tailored to meet your exact needs.
AMRA® Researcher software delivers:
We understand that you need to know if your drug candidate works and if it is safe—as efficiently and economically as possible.
Our services can help you detect treatment efficacy and identify non-responders early by capturing small physiological changes throughout the body.
Our whole-body MRI protocol, three muscle biomarkers, and automated image analysis can help you understand the full effect of a drug candidate—for an individual and an individual muscle.
Many muscle-related diseases slowly progress over time, and it is important to understand how the disease changes between stages and between individuals to develop effective interventions.
We create solutions that help you capture the full heterogeneity of disease and look at the muscles where you believe there is a progression of disease and at the muscles you want to save (intermediate muscles).
Our standardized whole-body approach gives you a good characterization of various muscle diseases—and different stages within those muscles.
Neuromuscular disorders are infamous for variable onset and progression—making clinical trials and disease research particularly challenging.
AMRA can help you gauge when to shift your assessment from muscles that are wasted—where measurements don’t add value—to other muscles that are healthier, making it easier to detect meaningful changes.
Notably, some muscles are affected earlier than others, and this can vary from patient to patient. We help you identify and include patients in different stages of the disease within the same trial.
For any given study participant, you can determine which muscles need to be assessed and monitored, and can get an idea of when to change course to get the data and insights you need to propel your research forward.
With precise MR image analysis and extensive experience in regulatory consulting on MRI biomarker strategy, AMRA is a trusted partner for clinical researchers ready to push precision medicine forward with body composition analysis.
AMRA has demonstrated unrivalled expertise in MRI biomarker regulatory strategy. Notably, in neuromuscular disorders (NMD) clinical trial partners are finding AMRA’s services particularly advantageous. Beyond precise, individualized MRI-based muscle biomarkers—which are FDA 21 CFR 11 compliant—AMRA offers strategic regulatory insights for the entirety of a clinical program—from before proof of concept through drug approval for multiple indications, accelerating clinical trials and the path to market approval.
Automated Segmentation,
Quantification & QA
Get results you can trust. Our solutions are 21 CFR Part 11 Compliant and we ensure quality-controlled, secure data transfers.
Tell us how you are using MRI for body composition analysis and let’s power the future of medicine together.